Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
Details
Publication Year 2024-02,Volume 63,Issue #2,Page 171-182
Journal Title
Clinical Pharmacokinetics
Publication Type
Research article
Abstract
BACKGROUND AND OBJECTIVE: Lorlatinib is a tyrosine kinase inhibitor approved for the treatment of advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. This study assessed the effect of steady-state lorlatinib on the metabolic enzymes cytochrome P450 (CYP) 2B6, CYP2C9, and uridine 5'-diphospho-glucuronosyltransferase (UGT) and the P-glycoprotein (P-gp) transporter. METHODS: Thirty-two patients received a single oral dose of a probe drug on Day - 2 to determine the pharmacokinetics of the probe drug alone. Starting on Day 1, patients received 100 mg oral lorlatinib daily. On Day 15, a single oral dose of the probe drug was administered concurrently with lorlatinib. Pharmacokinetic parameters for these probe substrates were assessed. RESULTS: Plasma exposures of all probe substrates were reduced by lorlatinib compared with the probe alone. The greatest reduction in area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) and maximum (peak) plasma drug concentration (C(max)) (67% and 63% decrease, respectively) was observed with the P-gp probe substrate fexofenadine. Lorlatinib coadministration also decreased the AUC(∞) and C(max) of bupropion (CYP2B6 probe substrate) by 25% and 27%, tolbutamide (CYP2C9 probe substrate) by 43% and 15%, and acetaminophen (UGT probe substrate) by 45% and 28%, respectively. CONCLUSIONS: Lorlatinib is a net moderate inducer of P-gp and a weak inducer of CYP2B6, CYP2C9, and UGT after steady state is achieved with daily dosing. Medications that are P-gp substrates with a narrow therapeutic window should be avoided in patients taking lorlatinib; no dose modifications are needed with substrates of CYP2B6, CYP2C9, or UGT. CLINICALTRIALS: gov: NCT01970865.
Publisher
Springer Nature
Keywords
Humans; *Carcinoma, Non-Small-Cell Lung/drug therapy; Cytochrome P-450 CYP2C9/genetics; *Lung Neoplasms/drug therapy; Cytochrome P-450 CYP2B6; ATP Binding Cassette Transporter, Subfamily B, Member 1; Uridine; Glucuronosyltransferase/genetics; Drug Interactions; Lactams, Macrocyclic/adverse effects; *Aminopyridines; *Lactams; *Pyrazoles
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1007/s40262-023-01309-4
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-03-05 04:47:26
Last Modified: 2024-03-05 04:47:58

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙